You are here: Industry Insights > SARS-CoV-2

News List

Study finds anti-parasitic drug could kill coronavirus in 48 hours pharmaceutical-technology
April 07, 2020
Researchers from Biomedicine Discovery Institute (BDI) at Monash University in Australia have found that an anti-parasitic drug called Ivermectin could kill the novel coronavirus, SARS-CoV-2, within 48 hours in a laboratory setting.
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro sciencedirect
April 07, 2020
Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to
Possible coronavirus drug identified by Australian scientists worldpharmanews
April 06, 2020
A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute).
BGI Receives FDA Authorization for Real-Time SARS-CoV-2 Test americanpharmaceuticalreview
April 06, 2020
Gilead Sciences has announced that two Phase III studies to test the safety and efficacy of remdesivir in COVID-19 patients have begun.
Global confirmed Covid-19 cases exceed one million pharmaceutical-technology
April 06, 2020
Covid-19 cases have crossed one million globally, with the pandemic being responsible for more than 52,000 deaths so far.
Amgen and Adaptive Biotechnologies to develop Covid-19 drug pharmaceutical-technology
April 06, 2020
Amgen has partnered with Adaptive Biotechnologies to develop a drug candidate that could prevent and treat Covid-19 coronavirus infection.
Covid-19 vaccine candidate yields promising data in mice pharmaceutical-technology
April 06, 2020
Researchers at the University of Pittsburgh School of Medicine in the US have reported encouraging results from initial tests of a Covid-19 vaccine candidate, PittCoVacc, delivered using a fingertip-sized patch in mice.
Vir Biotechnology and Alnylam expand alliance for Covid-19 drugs pharmaceutical-technology
April 06, 2020
Vir Biotechnology and Alnylam Pharmaceuticals have expanded their multi-target infectious diseases alliance to include up to three targets for SARS-CoV-2, the novel coronavirus that causes Covid-19.
Bosch Developing COVID-19-(SARS-CoV-2) Rapid Testing Kit for Vivalytic Platform americanpharmaceuticalreview
April 03, 2020
Bosch is currently working on the development of a COVID-19 rapid testing kit for the Vivalytic platform and will launch this in April 2020.
FDA Releases SARS-CoV-2 Reference Grade Sequence Data americanpharmaceuticalreview
April 03, 2020
On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. The President of the United States declared a national emergency on March 13, 2020, in response to the COVID-19 outbreak in the United States.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page